Key Developments For Iridex Corp
Iridex Corp (IRIX.O) (Consolidated Issue listed on NASDAQ Global Market)
IRIDEX Introduces Modular Multi-Wavelength Laser Solution
IRIDEX announced the introduction of a Modular Multi-Wavelength laser photocoagulator solution. The Company's offering uses two wavelengths; yellow (577) and infrared (810).
IRIDEX Announces FDA Clearance For New Product Family Of IRIDEX IQ Laser Systems
IRIDEX announced the receipt of FDA 510(k) clearance for its Family of IRIDEX IQ Laser Systems. This clearance covers the IRIDEX IQ 532, IQ 577, IQ 630-670, and IQ 810 Laser Systems and their associated delivery devices to deliver laser energy in either CW-Pulse, MicroPulse or LongPulse mode. These Laser Systems are intended for a wide range of specific applications in the medical specialties of ophthalmology, ear, nose and throat (ENT)/otolaryngology and dermatology.
IRIDEX Completion Of New Loan Facility With Wells Fargo Bank
IRIDEX announced completion of an $8.0 million loan facility with Wells Fargo Bank which replaces its previous loan facilities with Mid-Peninsula Bank.
IRIDEX Announces James Mackaness As Chief Financial Officer
IRIDEX announced that James H. Mackaness, will join the Company as Chief Financial Officer effective January 2, 2008.
IRIDEX Appoints New President And Chief Executive Officer
IRIDEX announced that Barry Caldwell has resigned as the Company's President and Chief Executive Officer, and as a member of the Board of Directors, effective as of October 16, 2007. The Company has appointed Theodore A. Boutacoff, who is currently a member and Chairman of the Board of Directors, to serve as the Company's President and Chief Executive Officer.
